You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab
|
---|---|
Published in |
Allergy, Asthma & Clinical Immunology, February 2014
|
DOI | 10.1186/1710-1492-10-7 |
Pubmed ID | |
Authors |
Philippe Bégin, Tina Dominguez, Shruti P Wilson, Liane Bacal, Anjuli Mehrotra, Bethany Kausch, Anthony Trela, Morvarid Tavassoli, Elisabeth Hoyte, Gerri O’Riordan, Alanna Blakemore, Scott Seki, Robert G Hamilton, Kari C Nadeau |
Abstract |
Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen protein. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Argentina | 1 | 14% |
Singapore | 1 | 14% |
Romania | 1 | 14% |
United Kingdom | 1 | 14% |
Unknown | 3 | 43% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 71% |
Scientists | 2 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Korea, Republic of | 1 | 1% |
United States | 1 | 1% |
Argentina | 1 | 1% |
Unknown | 89 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 17 | 18% |
Researcher | 15 | 16% |
Student > Postgraduate | 9 | 10% |
Student > Ph. D. Student | 7 | 8% |
Student > Master | 7 | 8% |
Other | 15 | 16% |
Unknown | 22 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 36 | 39% |
Agricultural and Biological Sciences | 8 | 9% |
Biochemistry, Genetics and Molecular Biology | 6 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
Immunology and Microbiology | 5 | 5% |
Other | 4 | 4% |
Unknown | 28 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 83. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2023.
All research outputs
#511,338
of 25,374,647 outputs
Outputs from Allergy, Asthma & Clinical Immunology
#23
of 924 outputs
Outputs of similar age
#4,534
of 235,878 outputs
Outputs of similar age from Allergy, Asthma & Clinical Immunology
#1
of 31 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 924 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,878 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.